Evidence map›Paper›PMID 38213997›Full record

ArticleNAR cancer2024

Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN.

Jonatan L Gabre, Peter Merseburger, Arne Claeys, Joachim Siaw, Sarah-Lee Bekaert, Frank Speleman, Bengt Hallberg, Ruth H Palmer, Jimmy Van den Eynden

Open access · goldAbstract read
In one paragraph

Article in NAR cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jonatan L GabreDepartment of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University, Ghent, Belgium.ORCID 0000-0001-6278-7556
Peter MerseburgerDepartment of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University, Ghent, Belgium.ORCID 0000-0002-5154-8696
Arne ClaeysDepartment of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University, Ghent, Belgium.ORCID 0000-0001-6990-1569
Joachim SiawDepartment of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University, Ghent, Belgium.ORCID 0000-0002-1286-4485
Sarah-Lee BekaertCancer Research Institute Ghent, Ghent, Belgium.ORCID 0000-0002-4769-3460
Frank SpelemanCancer Research Institute Ghent, Ghent, Belgium.ORCID 0000-0002-6628-8559
Bengt HallbergDepartment of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-2032-2616
Ruth H PalmerDepartment of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-2735-8470
Jimmy Van den EyndenDepartment of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University, Ghent, Belgium.ORCID 0000-0003-0002-5614
Ghent University · BEUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma (NB) is the most common cancer in infancy with an urgent need for more efficient targeted therapies. The development of novel (combinatorial) treatment strategies relies on extensive explorations of signaling perturbations in neuroblastoma cell lines, using RNA-Seq or other high throughput technologies (e.g. phosphoproteomics). This typically requires dedicated bioinformatics support, which is not always available. Additionally, while data from published studies are highly valuable and raw data (e.g. fastq files) are nowadays released in public repositories, data processing is time-consuming and again difficult without bioinformatics support. To facilitate NB research, more user-friendly and immediately accessible platforms are needed to explore newly generated as well as existing high throughput data. To make this possible, we developed an interactive data centralization and visualization web application, called CLEAN (the Cell Line Explorer web Application of Neuroblastoma data; https://ccgg.ugent.be/shiny/clean/). By focusing on the regulation of the DNA damage response, a therapeutic target of major interest in neuroblastoma, we demonstrate how CLEAN can be used to gain novel mechanistic insights and identify putative drug targets in neuroblastoma.

Indexed as

DNA DamageNeuroblastomaCell Line, TumorComputational BiologyHumansSignal Transduction

Identifiers

PMID38213997
PMCPMC10782898
OpenAlexW4390753241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.